Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics

Abstract This review focuses on (i) the current status of 1H NMR spectroscopy to quantify lipoprotein subclasses directly from serum or plasma, and (ii) the applications of 1H NMR metabonomics of serum in biomedicine. Related to both themes, experimental and data analysis methodologies are discussed together with the biochemical rationales. Particular emphasis is placed on the concepts of risk assessment and diagnostics in relation to the potential clinical role of 1H NMR metabonomics; recent applications in the area of coronary heart disease and diabetes are addressed in more detail. Clin Chem Lab Med 2008;46:27–42.

[1]  Doris M Jacobs,et al.  Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. , 2006, Analytical biochemistry.

[2]  E Holmes,et al.  Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. , 2002, The Analyst.

[3]  D W Bennett,et al.  Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. , 1991, Clinical chemistry.

[4]  M. Dyrby,et al.  Quantification of lipoprotein subfractions using 1H-NMR and chemometrics , 2003 .

[5]  Kimmo Kaski,et al.  Characterization and molecular detection of atherothrombosis by magnetic resonance—potential tools for individual risk assessment and diagnostics , 2006, Annals of medicine.

[6]  R. Koopman,et al.  Predicting coronary heart disease risk using multiple lipid measures. , 2005, The American journal of cardiology.

[7]  D. Levy,et al.  Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study , 2005, Circulation.

[8]  Johan Trygg,et al.  Chemometrics in metabonomics. , 2007, Journal of proteome research.

[9]  Jimmy D Bell,et al.  Factors affecting 1h NMR spectra of blood plasma: cancer, diet and freezing , 1988, NMR in biomedicine.

[10]  D. Arnett,et al.  Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load. , 2004, Clinical chemistry.

[11]  Moyses Szklo,et al.  LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Atherosclerosis.

[12]  Elaine Holmes,et al.  Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. , 2006, Journal of proteome research.

[13]  I. Wilson,et al.  Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. , 2004, Journal of pharmaceutical and biomedical analysis.

[14]  John C Lindon,et al.  Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma. , 2004, Analytical biochemistry.

[15]  Elaine Holmes,et al.  The challenges of modeling mammalian biocomplexity , 2004, Nature Biotechnology.

[16]  S. Soedamah-Muthu,et al.  Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999 , 2003, Diabetologia.

[17]  Aki Vehtari,et al.  A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data , 2007, BMC Bioinformatics.

[18]  Rasmus Bro,et al.  Analysis of lipoproteins using 2D diffusion-edited NMR spectroscopy and multi-way chemometrics , 2005 .

[19]  P J Sadler,et al.  Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. , 1984, The Biochemical journal.

[20]  G. Hitman,et al.  The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. , 2003, Atherosclerosis.

[21]  J. M. Carr,et al.  Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. , 1986, The New England journal of medicine.

[22]  U. Engelke,et al.  Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism , 2003, Annals of clinical biochemistry.

[23]  Jimmy D Bell,et al.  Quantification of biomedical NMR data using artificial neural network analysis: Lipoprotein lipid profiles from 1H NMR data of human plasma , 1995, NMR in biomedicine.

[24]  Anthony F. P. Nash,et al.  A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. , 2003, Journal of pharmaceutical and biomedical analysis.

[25]  M. Taskinen,et al.  Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. , 2002, Diabetes.

[26]  Alan Hutson,et al.  Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.

[27]  N. Serkova,et al.  Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics , 2006, Expert review of molecular diagnostics.

[28]  W. Cromwell,et al.  Low-density lipoprotein particle number and risk for cardiovascular disease , 2004, Current atherosclerosis reports.

[29]  T. Orchard,et al.  Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 Diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2003, Diabetologia.

[30]  A. Fernie,et al.  Metabolite profiling: from diagnostics to systems biology , 2004, Nature Reviews Molecular Cell Biology.

[31]  Elaine Holmes,et al.  Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis , 2004, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[32]  J. Nicholson,et al.  Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. , 2003, The Analyst.

[33]  M Ala-Korpela,et al.  1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. , 1994, Journal of lipid research.

[34]  R. D'Agostino,et al.  Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study , 2005, Circulation.

[35]  S. Haffner,et al.  Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. , 2005, Metabolism: clinical and experimental.

[36]  C. Heward,et al.  Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. , 2006, Clinical chemistry.

[37]  J. Griffin.  The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[38]  Kimmo Kaski,et al.  The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. , 2007, Atherosclerosis.

[39]  John C. Lindon,et al.  Use of 1H NMR‐determined diffusion coefficients to characterize lipoprotein fractions in human blood plasma , 2002 .

[40]  W. Cromwell,et al.  Measurement issues related to lipoprotein heterogeneity. , 2002, The American journal of cardiology.

[41]  A. Nitenberg,et al.  Postprandial endothelial dysfunction: role of glucose, lipids and insulin. , 2006, Diabetes & metabolism.

[42]  D. Leibfritz,et al.  Visualizing metabolic changes in breast‐cancer tissue using 1H‐NMR spectroscopy and self‐organizing maps , 2003, NMR in biomedicine.

[43]  K. Kaski,et al.  1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self‐organising maps , 2007, NMR in biomedicine.

[44]  B. Zetter,et al.  Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.

[45]  V. Fuster,et al.  Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis , 2004, Journal of Thrombosis and Thrombolysis.

[46]  K. Kaski,et al.  Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum , 2007, Magnetic Resonance Materials in Physics, Biology and Medicine.

[47]  R. Kauppinen,et al.  A metabolomics perspective of human brain tumours , 2007, The FEBS journal.

[48]  Mika Ala-Korpela,et al.  1H NMR spectroscopy of human blood plasma , 1995 .

[49]  T. Bathen,et al.  Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis , 2000, NMR in biomedicine.

[50]  A. Jenkins,et al.  Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. , 2004, Metabolism: clinical and experimental.

[51]  Nicholas J Wareham,et al.  Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. , 2007, Journal of the American College of Cardiology.

[52]  P. Valensi,et al.  Serum 1H‐nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients , 2005, NMR in biomedicine.

[53]  Ian D Wilson,et al.  Analytical strategies in metabonomics. , 2007, Journal of proteome research.

[54]  T. Lyons,et al.  Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. , 2003, Metabolism: clinical and experimental.

[55]  R. Hewer,et al.  Applying biofluid 1H NMR-based metabonomic techniques to distinguish between HIV-1 positive/AIDS patients on antiretroviral treatment and HIV-1 negative individuals. , 2006, Journal of pharmaceutical and biomedical analysis.

[56]  Julian L Griffin,et al.  Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. , 2003, Current opinion in chemical biology.

[57]  Christophe Ladroue,et al.  Independent component analysis for automated decomposition of in vivo magnetic resonance spectra , 2003, Magnetic resonance in medicine.

[58]  Wolfgang Rosenstiel,et al.  Neural Networks Evaluating NMR Data: An Approach To Visualize Similarities and Relationships of Sol-Gel Derived Inorganic-Organic and Organometallic Hybrid Polymers1 , 2002, J. Chem. Inf. Comput. Sci..

[59]  Markku J. Savolainen,et al.  STRUCTURAL CHANGES OF LIPOPROTEIN LIPIDS BY 1H NMR , 1995 .

[60]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[61]  R. Krauss,et al.  Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. , 1992, Clinical chemistry.

[62]  Zahi A. Fayad,et al.  Molecular, cellular and functional imaging of atherothrombosis , 2004, Nature Reviews Drug Discovery.

[63]  John C Lindon,et al.  Sample classification based on Bayesian spectral decomposition of metabonomic NMR data sets. , 2004, Analytical chemistry.

[64]  Julian L Griffin,et al.  Proton NMR analysis of plasma is a weak predictor of coronary artery disease , 2006, Nature Medicine.

[65]  D. Lackland,et al.  Nuclear magnetic resonance‐determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima‐media thickness , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[66]  An NMR blood test for cancer: a critical assessment. , 1989, NMR in biomedicine.

[67]  B. Goodfellow,et al.  Metabolic characterisation of plasma in juveniles with glycogen storage disease type 1a (GSD1a) by high‐resolution 1H NMR spectroscopy , 2007, NMR in biomedicine.

[68]  Elaine Holmes,et al.  Impact of analytical bias in metabonomic studies of human blood serum and plasma. , 2006, Analytical chemistry.

[69]  J. van der Greef,et al.  The role of analytical sciences in medical systems biology. , 2004, Current opinion in chemical biology.

[70]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[71]  P. McBride,et al.  Should advanced lipoprotein testing be used in clinical practice? , 2006, Nature Clinical Practice Cardiovascular Medicine.

[72]  R. Superko.  Lipoprotein subclasses and atherosclerosis. , 2001, Frontiers in bioscience : a journal and virtual library.

[73]  T. Ebbels,et al.  Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. , 2002, Chemical research in toxicology.

[74]  J. Trygg,et al.  Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. , 2005, Analytical chemistry.

[75]  Robert S Plumb,et al.  Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. , 2006, Analytical chemistry.

[76]  J. Nicholson.  Global systems biology, personalized medicine and molecular epidemiology , 2006, Molecular systems biology.

[77]  D. Gauguier,et al.  Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.

[78]  R. D'Agostino,et al.  Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. , 2004, Clinical chemistry.

[79]  M Ala-Korpela,et al.  Application of self‐organizing maps for the detection and classification of human blood plasma lipoprotein lipid profiles on the basis of 1H NMR spectroscopy data , 1998, NMR in biomedicine.

[80]  Truman R. Brown,et al.  NMR Spectral Quantitation by Principal Component Analysis. , 2002 .

[81]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[82]  M. Taskinen,et al.  Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresiss⃞s⃞ The online version of this article (available at http://www.jlr.org) contains an additional two tables. Published, JLR Papers in Press, March 1, 2004. DOI 10.1194/jlr.M300395-JLR200 , 2004, Journal of Lipid Research.

[83]  A. Jenkins,et al.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.

[84]  J. Pulkkinen,et al.  Independent component analysis to proton spectroscopic imaging data of human brain tumours. , 2005, European journal of radiology.

[85]  Ken Williams,et al.  Nuclear Magnetic Resonance Lipoprotein Abnormalities in Prediabetic Subjects in the Insulin Resistance Atherosclerosis Study , 2005, Circulation.

[86]  S. Soedamah-Muthu,et al.  Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999 , 2002, Diabetologia.

[87]  Mattias Rantalainen,et al.  Statistical correlation and projection methods for improved information recovery from diffusion-edited NMR spectra of biological samples. , 2007, Analytical chemistry.

[88]  J. Otvos,et al.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. , 2002, Clinical laboratory.

[89]  Jimmy D Bell,et al.  1H NMR studies of human blood plasma Assignment of resonances for lipoproteins , 1987, FEBS letters.

[90]  D. Lackland,et al.  Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. , 2003, Diabetes care.

[91]  E. Dow,et al.  Automated analysis of proton NMR spectra from combinatorial rapid parallel synthesis using self-organizing maps. , 2002, Journal of combinatorial chemistry.

[92]  W. Cromwell,et al.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.

[93]  J. Otvos,et al.  Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. , 2005, Atherosclerosis.

[94]  D. Lackland,et al.  Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. , 2004, Investigative ophthalmology & visual science.

[95]  Søren Balling Engelsen,et al.  Quantification of lipoprotein subclasses by proton nuclear magnetic resonance-based partial least-squares regression models. , 2005, Clinical chemistry.

[96]  I. Wilson,et al.  Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.

[97]  Brian C Sweatman,et al.  Optimisation of collection, storage and preparation of rat plasma for 1H NMR spectroscopic analysis in toxicology studies to determine inherent variation in biochemical profiles. , 2002, Journal of pharmaceutical and biomedical analysis.